Search
Displaying 231–240 of 526 for “Retinitis pigmentosa”
-
Cleanlogic Co-Founder’s Inspiration Comes From His Mom
Beacon StoriesIn honor of Mother’s Day, we’re sharing a special Beacon Story featuring Isaac Shapiro, co-founder of Cleanlogic. Isaac’s mother, Bea, lost her vision at only seven years old but went on to become an entrepreneur and help others in the blind and visually impaired community through adaptive technology.
-
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Research NewsEditas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
-
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
Research NewsThe drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors
-
Aldeyra Launches Phase 2 Clinical Trial of Methotrexate Intravitreal Injections for RP
Research NewsLab studies showed the drug can effectively address the misfolded rhodopsin protein
-
Advocating for the Foundation Through Professional Outreach
Beacon StoriesAs a longtime supporter and advocate for the Foundation Fighting Blindness, Lora has recently begun working with the Professional Outreach team. Lora’s work helps eye care professionals in the Philadelphia region provide vital resources for their patients with inherited retinal diseases.
-
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Research NewsCompany has been unable to meet revenue goals for the Argus II®
-
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
Research NewsThe emerging treatment had shown encouraging results in a Phase ½ clinical trial
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
.png)
